9ZT8
Stabilized SARS-CoV-2 S2 apo
Summary for 9ZT8
| Entry DOI | 10.2210/pdb9zt8/pdb |
| EMDB information | 74740 |
| Descriptor | Spike protein S2, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total) |
| Functional Keywords | sars-cov-2, coronavirus, immune system, antibody, viral protein |
| Biological source | Severe acute respiratory syndrome coronavirus 2 |
| Total number of polymer chains | 3 |
| Total formula weight | 162173.08 |
| Authors | |
| Primary citation | Park, S.,Mischka, J.,Okba, N.,Abbad, A.,Yuan, M.,Srivastava, K.,Gleason, C.,Mulder, L.C.F.,Copps, J.,Saam, K.,Bangaru, S.,Krammer, F.,Wilson, I.A.,Simon, V.,Ward, A.B. The buried S2 apex of SARS-CoV-2 spike elicits an immunodominant germline-restricted public antibody response. Biorxiv, 2026 Cited by PubMed Abstract: The continued mutational pressure on the SARS-CoV-2 S1 subunit underscores the need to target the conserved S2 region for pan-coronavirus vaccine development. A detailed molecular understanding of S2-directed immune responses is therefore essential. In this study, we identified the S2 apex as the most immunodominant epitope within the S2 subunit, eliciting robust antibody responses despite occlusion by S1, using electron-microscopy-based polyclonal epitope mapping (EMPEM) of plasma from infected and vaccinated individuals. Structure-guided sequence analysis with antibody databases revealed that antibodies targeting a poorly characterized S2 Apex-B site form a convergent public clonotype, which is predominantly derived from the IGHV3-30 germline with a 14-residue CDRH3 containing a G/S-G-S/N-Y motif. This clonotype is extensively expanded, accounting for up to 40% of total spike-reactive antibody sequence counts in individual vaccinated donors. This study elucidates the molecular basis the high-frequency elicitation of this non-neutralizing clonotype emphasizing that its immunodominance acts as a primary hurdle for universal coronavirus vaccines and underscore the need for precision antigen design to redirect immunity toward more potent neutralizing targets. PubMed: 41756886DOI: 10.64898/2026.02.18.706653 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (2.75 Å) |
Structure validation
Download full validation report






